Skip to main content

Biosimilars

Biosimilars

Real-World Trends in Biosimilar Prescribing Among Oncology Providers

Biosimilars

Real-World Utilization and Cost Patterns with Biosimilar and Filgrastim Reference in a Community Oncology Setting

Biosimilars

Real-World Evidence of Bevacizumab-awwb Use in a Population of Patients with Cancer

Biosimilars

Same-Day Pegfilgrastim-cbqv Administration Is Feasible in Patients with Breast Cancer Receiving Myelosuppressive Chemotherapy Regimens

Biosimilars

Real-World Evidence of Cardiac Safety of Trastuzumab Biosimilar Trastuzumab-anns in Breast Cancer

Biosimilars

Incidence of Hypertension and Proteinuria in Bevacizumab- and Bevacizumab Biosimilar-Treated Cohorts

Biosimilars

Cost-Efficiency Analysis of Switching from Reference Pegfilgrastim to Pegfilgrastim-jmdb

Biosimilars

Real-World Data Showed Comparable pCR Rates with Neoadjuvant Chemotherapy plus Trastuzumab-dkst versus Trastuzumab

Biosimilars

Cost-Effectiveness of Subcutaneous Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf for the Treatment of High-Risk, HER2-Positive Early Breast Cancer

Biosimilars

Real-World Overall Response Rate and Other Outcomes Related to Originator and Biosimilar Rituximab in Patients with CLL or NHL in the United Kingdom

1
2
3
4
5
6
7

Page 4 of 8
Results 31 - 40 of 73